Halozyme Therapeutics (HALO) FY2018 results: revenue $152 million, down 52.0% on the year
Halozyme Therapeutics, Inc. (HALO) reported revenue of $152 million for fiscal 2018, the year ended 31 December 2018, down 52.0% on the year before. Net income was -$80 million, and diluted earnings per share $-0.56. The figures are the company's own, from the 10-K it filed with the SEC on 21 February 2019.
Revenue
$152 million
-52.0% on the year
FY2011FY2018
Operating margin
-45.7%
25.6% a year earlier
FY2011FY2018
Net income
-$80 million
FY2011FY2018
Diluted EPS
-$0.56
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
152
317
147
-52.0%
Cost of revenue
10.1
31.2
33.2
-67.5%
Gross profit
142
285
113
-50.4%
Gross margin
93.3%
90.2%
77.4%
Research and development
150
151
151
-0.3%
Selling, general and administrative
60.8
53.8
45.9
+13.0%
Operating income
-69.3
81.0
-83.2
Operating margin
-45.7%
25.6%
-56.7%
Interest expense
18.0
22.0
20.0
-17.9%
Pre-tax income
-79.8
61.6
-102
Income tax
0.5
-1.4
1.2
Effective tax rate
n/a
-2.2%
n/a
Net income
-80.3
63.0
-103
Net margin
-52.9%
19.9%
-70.2%
Diluted EPS
-$0.56
$0.45
-$0.81
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-49.5
134
-50.4
Capital expenditure
4.7
1.4
3.1
+245.4%
Free cash flow
-54.2
133
-53.5
Free cash flow margin
-35.7%
41.9%
-36.5%
Cash from investing
2.5
-164
-76.8
Cash from financing
-63.8
132
151
Depreciation and amortisation
2.4
2.2
2.4
+10.5%
Share-based compensation
35.7
30.7
25.6
+16.4%
Buybacks
0.0
0.0
n/a
Diluted shares, weighted
144m
139m
128m
+3.3%
Shares outstanding at period end
143m
143m
130m
0.0%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
249
208
-32.5
+19.4%
Debt
126
202
217
-37.5%
Other liabilities
65.0
109
77.4
-40.5%
Total liabilities and equity
440
520
262
-15.3%
Fixed assets
7.5
3.5
4.3
+112.1%
Investments
297
300
138
-1.3%
Cash and equivalents
57.9
169
66.8
-65.7%
Receivables
30.0
22.1
15.7
+35.6%
Inventory
22.6
5.1
14.6
+339.7%
Other assets
25.6
19.9
22.0
+28.6%
Total assets
440
520
262
-15.3%
10-K for the year ended 31 December 2018, filed 21 February 2019: the filing.